Using dataset with papers published till 2000


Alzheimer's disease is caused by a highly selective neurodegenerative process. Therefore, the mechanism of amyloid deposition and progression  is a multifaceted, multi-system biology.
The effect of the apolipoprotein E4 receptor antagonist, apolipoprotein E4, on the activity of an immunohistochemical assay for the carboxyl-terminal domain of the apolipoprotein E4 receptor was examined in postmortem human brain. The presence of a high concentration of the apolipoprotein E4 receptor was also observed in the cerebral cortex. There was a striking effect on the level of the apolipoprotein E4 receptor binding to the apolipoprotein E4 receptor. In contrast, the binding of the apolipoprotein E4 receptor was not altered in the cerebral cortex in the frontal cortex or in the temporal cortex. These findings suggest that apolipoprotein E4 receptor activation is an important part of the apolipoprotein E4 receptor system.
The amiridin-responsive protein family was identified from the parietal and temporal cortex of the infant rat brain. A beta-protein  fragment, the beta-protein of which is expressed in the galanin-responsive protein family, was found
====================
Alzheimer's disease is caused by genetic mutation of the apolipoprotein E gene in humans. The apoE2 allele is a risk factor for the disease; therefore, we cannot exclude an association between the apoE2 allele and the disease. There are several studies suggesting that the apoE2 allele is a risk factor for the disease. However, these may be of a delay or have no effect on the age at onset. The other risk factors for the disease include the risk of hypertension and cardiovascular disease, and the presence of a familial form of Alzheimer's disease. Furthermore, the apoE2 allele is a risk factor for the disease in an earlier age at onset.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that results in progressive memory impairment, language disturbance, and slowing of cognitive processing. The disorder is characterized by  a progressive loss of cognitive functions, with major impairments in the ability to understand and to perform complex tasks in the absence of specific cognitive impairment. Although the disease has been classified into three types (multi-infarct, multi-infarct multi-infarct, and multi-infarct multi-infarct), the  clinical and neuropathologic features that distinguish
====================
Alzheimer's disease is caused by a genetic mutation in the presenilin-1 gene. The vulnerability of APP to apoptosis is known to be mediated by a specific gene called presenilin-2. The expression of presenilin-2 strongly increases in the brain of the mice overexpressing APP. This is in contrast to the homeostatic effects of APP, which is expressed by neurons, in the brains of patients with Alzheimer's disease. Presenilin-2 is also expressed in the brain of patients with cerebrovascular disease. The expression of presenilin-2 in the brain of patients with vascular dementia may reflect the hypothalamic-pituitary-adrenal axis.
Many studies have shown that amyloid beta-peptide (A beta) is released from the beta-end-peptide (beta-AP) pathway in a variety of tissues, including brain. A beta is released as a soluble protein found in the amyloid beta-peptide (A beta) protein depositions during the development of the amyloid deposits. In this study, we examined whether A beta production by the soluble A beta precursor protein (APP) interacts with the soluble A beta precursor protein
====================
Alzheimer's disease is caused by an imbalance in the depletion of biologically active hydroxyl radical energy in the brain. This energy imbalance leads to the dysfunction of the phytohemagmin pathway, which is the primary pathologic process in Alzheimer's disease; this process is disturbed in several brain regions, including the hippocampus, the  prefrontal cortex, and the hypothalamus. In addition, the amyloid-beta peptide, a major component of the senile plaques which accumulate in the brains of Alzheimer's disease patients, is also  found to be depleted in the brain in response to excitotoxic insults. Thus, potential mechanisms of the phosphomonoester system in brain are elucidated.
The A beta peptide (A beta) is the principal constituent of amyloid plaques in Alzheimer's disease which are composed primarily of the beta A4 peptide. The A beta peptide is deposited in paraffin-embedded cerebral microvessels, and it is localized as secretory amyloid precursor protein (APP). A beta peptide is a multipolar proteolytic marker of APP processing and secretion. A beta peptide is resistant to proteolysis and is less able to break down the amyloid beta peptide.
====================
Alzheimer's disease is caused by genetic factors. The genetic influence of the amyloid beta-peptide is discussed in this paper.
Apolipoprotein E (apoE) is a cholesterol-lowering protein found in the brain,  and its role in the regulation of the blood pressure is unknown. Overexpression of apoE by the human apoE4 allele was shown to be an important risk factor in Alzheimer's disease, and previously expressed apoE was shown to be a risk factor for the development of Parkinson's disease, depression, and Alzheimer's disease. The apoE gene was previously shown to be a risk factor for late-onset Alzheimer's disease and is likely to be important in the pathogenesis of these diseases. However, apoE4, a polymorphic apoE4 gene, was not detected in the serum of normal individuals. We now report that the dosage of the apoE4 allele in serum is not associated with the development of Alzheimer's disease. The study also found a significant positive interaction between the apoE4 allele and apoE4 in the development of Alzheimer's disease.
The apolipoprotein E (apoE) isoform is a necessary substrate for the normal
====================






Alzheimer's disease should be treated with cholinesterase inhibitors.
1. The ability of a cholinergic factor, choline acetyltransferase (ChAT), to treat Alzheimer's disease (AD), is unclear. 2. The cholinergic hypothesis has been based on the hypothesis that cholinergic mechanisms of action are intact in AD and,  in addition to their function in the normal aging process, the hypothesis that cholinergic mechanisms of action in AD are intact. 3. A number of studies have shown that a cholinergic neurotransmitter, choline acetyltransferase (ChAT), can reverse the destruction of acetylcholine (ACh), a cholinergic neurotransmitter. 4. Recently, choline acetyltransferase (ChAT) inhibitors, eicosapentaenoic acid (EPA), can have an effect on acetylcholine release from plasma or from cholinergic neurons of the central nervous system (CNS). 5. The role of ChAT in the prevention, treatment, and prevention of AD is unclear. 6. To clarify whether ChAT is an effective treatment  for AD, we have analyzed ChAT activity in the cerebellum and hippocampus in Alzheimer's disease (AD) patients. 7
====================
Alzheimer's disease should be treated with tacrine or muscarinic agonists. A possible treatment strategy for dementia is to increase the amount of acetylcholine available to the brain in the treatment of the disease. From an understanding of the role of acetylcholine in the central nervous system, the development of a treatment strategy could be a very useful means of improving the quality of life for patients with dementia.
Apolipoprotein E (apoE) is a large protein low in free amino acid (FA) and it is a major constituent of the apolipoprotein E gene (APOE) genotype and epsilon4 allele. ApoE is also related to the  apolipoprotein E4 allele in two other human diseases, Alzheimer's disease (AD), and vascular dementia. In this study, we investigated the association of apoE genotype with the number of incident cases of AD, vascular dementia, and chronic renal failure (CVD). We found no association between  apoE genotype and the number of incident cases of CVD. There was no evidence of an association of apoE genotype with the number of incident cases of AD, vascular dementia, and chronic renal failure (CVD). ApoE was also
====================
Alzheimer's disease should be treated with pharmacological treatment.
Alzheimer's disease is a multifaceted, multi-infarct dementia that is a contributory cause of dementia. The neuropathologic findings of the neuropathologic and clinical trials of the anticonvulsant anticonvulsants are the most complete and reliable in demonstrating the clinical and neurochemical characteristics of Alzheimer's disease and its etiology. More so, the clinical and neuropathologic investigations that have been carried out on the clinical and neurochemical basis of Alzheimer's disease are the most fruitful in showing the etiology of the disease and its pathogenesis.
We now report that the SOD-1 antigen is expressed in the cerebral cortex of individuals with AD. The effect of SOD-1 on SOD-1 mRNA expression is discussed and tested.
The immunohistochemical features of senile plaques in the brains of patients with Alzheimer's disease are examined in comparison with those in the brains of subjects with other dementing disorders. In particular, the plaques were found to be composed of a large number of paired helical filaments (PHF), different in shape and density from those of the PHF in normal and AD brains. The density of PHF in the
====================
Alzheimer's disease should be treated with the same dosage of amyloid precursor protein.
An international investigation was performed in the Central African Republic  to assess the prevalence of dementia in the population aged 65 years or more. The study was designed to examine the prevalence of dementia in the population aged 65 years or more over a period of 3.5 years. Twenty-four cases of dementia in the population aged 65 years or more were compared to 20 cases of dementia in the population aged 60 years or more over a period of 3.5 years. The prevalence had no significant effect on age, education, sex, age at death, or the extent of education. There was no difference in the prevalence of dementia among the population aged 60 years or more over a period of 3.5 years. There was no difference in the prevalence of dementia in the population aged 60 years or more over a period of 3.5 years among the population aged 60 years or more over a period of 2.5 years. The prevalence of dementia did not differ across the disease stages.
The last of the periodic table (PDS) documents the distribution of mental status in the population aged 65 years or more. Mental status has been measured in a relatively large number of people in a number of different countries.
====================
Alzheimer's disease should be treated with SMA.
OBJECTIVE: To study the influence of the Alzheimer Disease Assessment Scale (ADAS) and the family history of the diagnosis of senile dementia of the Alzheimer type (SDAT) on the level of education in a sample of AD patients. DESIGN: A survey of the family history of the diagnosis of senile dementia of the Alzheimer type (SDAT) and the family history of the diagnosis of SDAT was conducted by telephone interviews. SETTING: The Study is a prospective study of the development of a diagnostic test battery for the diagnosis of SDAT. PARTICIPANTS: Two hundred and fifty-one patients  age 65 years and older, with an average age of 66.7 years were followed for 2 1/2 years. The sample consisted of 55 patients diagnosed as suffering from PD or Alzheimer disease, and the family history of the diagnosis of SDAT was examined prospectively in a multivariate model. INTERVENTION: On the basis of  age and family history of the diagnosis of SDAT, the ADAS and the family history of SDAT were administered to the patients. RESULTS: The ADAS score was significantly lower among the patients with  SDAT than among the patients with  PD
====================







Alzheimer's disease is characterized by the accumulation of beta-amyloid peptide (beta-AP) throughout the brain. In the transgenic model, the A beta peptide amyloid precursor protein is localized in the Golgi apparatus in the brainstem, and the Golgi apparatus appears to be  a central control system for the generation of APP. In GBS, the density of soluble APP was determined in the hippocampus, but did not differ by the APP genotype or the APP genotype. In the transgenic mouse model, the density of APP was found in the cerebral cortex of the transgenic mice, and the density of APP was found in the hippocampus. In the transgenic mouse model, the density of APP was found in the cerebral cortex of the transgenic mice, and the density of APP was found in the hippocampus. However, the density of APP was not different between transgenic mice and transgenic mice in the hippocampus, and no difference was found between transgenic mice and transgenic mice in the temporal cortex. In the transgenic mouse model, the density of APP was found in the cerebral cortex of the transgenic mice, and the density of APP was found in the hippocampus. In the transgenic mouse model, the density of APP was found
====================
Alzheimer's disease is characterized by the presence of neurofibrillary changes and amyloid fibril formation. In the present study, we have characterized the extent of amyloid fibril formation in the neuritic and diffuse plaques of Alzheimer's disease. These plaques were composed of amyloid fibrils, and the extent of amyloid fibril formation was not quantitatively altered. The extent of amyloid fibril formation was higher at the neuritic and diffuse plaques, and this difference was less pronounced in the diffuse plaques. Our results indicate that, in addition to the amyloid fibrils, the diffuse plaques contain tau protein and an altered tau isoform.
A consistent finding in the literature is the prevalence of Alzheimer's disease (AD) among early-onset (adult) aging individuals. To examine the relationship between AD prevalence and the prevalence of AD among late-onset (AD) individuals, the prevalence of mild cognitive impairment, as measured by the Mini-Mental State Examination, was correlated with the diagnosis of AD with a P value of 0.64 (p less than 0.001). We found that the familial risk of AD for AD was 0.28 (p
====================
Alzheimer's disease is characterized by progressive neurodegeneration and memory loss. The present study attempted to address this issue through a neuropathologic approach to the study of Alzheimer's disease, using an immunoelectron microscopic method with a monoclonal antibody raised against the microtubule associated protein tau. In addition, we administered a tau monoclonal antibody against a monoclonal antibody raised against the microtubule associated protein tau, which specifically recognized the neurofibrillary tangles of Alzheimer's disease. The immunoreactive neurofibrillary tangles of Alzheimer's disease were also recognized by the microtubule associated protein tau. This neurofibrillary tangles were also immunopositive to a monoclonal antibody raised against tau. Immunohistochemical studies of the microtubule associated protein tau were performed in the presence of the antibody. The microtubule-associated protein tau was immunoreactive to the antibody raised against the microtubule associated protein tau and the microtubule-associated protein tau in the presence of the antibody. When immunohistochemically  labeled, the microtubule-associated protein tau was  labeled with a monoclonal antibody,
====================
Alzheimer's disease is characterized by the presence of both amyloid deposits and neurofibrillary tangles (NFTs). In the present study, the extent to which the expression of the PrP-receptor gene, as well as the expression of the synapse-specific gene PrP-receptor gene, were determined in eight Alzheimer's disease cases and eight normal controls were analyzed. The extent to which the PrP-receptor gene expression was reduced was determined by the expression of the synapse-specific gene PrP-receptor gene and by the expression of the synapse-specific gene PrP-receptor gene in the two groups. The PrP-receptor gene expression was not affected by the presence or absence of NFTs. Furthermore, in the normal group, the expression of the synapse-specific gene PrP-receptor gene was significantly reduced. The extent of PrP-receptor gene expression was not affected by NFTs. The PrP-receptor gene expression was reduced in both groups of cases, and the PrP-receptor gene expression was decreased in the Alzheimer's disease group. This study demonstrates that PrP-receptor gene expression is reduced in Alzheimer's disease.
1. The authors
====================
Alzheimer's disease is characterized by an autosomal dominant sequence of Alzheimer's disease mutations, and the gene is located on chromosome 11.
The present study examined the ability of young, adult, and old adult male Sprague-Dawley rats to carry the C4 protein, a constitutive protein of neurons and astrocytes in both the striatum and hippocampus. These animals were a significant model of developmentally-dependent plasticity, and have a high level of activation of cholinergic neurons in their hippocampus.
The use of a validated test battery to measure the performance of young adults in a variety of tasks was used to evaluate the learning of a group of patients with a range of learning impairments. The mean age of the patients was 35, while the mean age of the subjects was 56. The data were analyzed by means of Student's exact test. The mean age of the patients was 36. The mean age of the subjects was 56. The mean age of the subjects was 56. The mean age of the subjects was 56. The mean age of the subjects was 56. The mean age of the subjects was 56. The mean age of the subjects was 66. The mean age of the subjects was 62. The mean age of the subjects was 62.
====================





Using dataset with papers published till 2010


Alzheimer's disease is caused by mutations in the presenilin-1 gene. We have shown previously that the presenilin 1 gene is present in the brain of a transgenic mouse expressing AD-associated amyloid beta (Abeta) plaques. We have now shown that the presenilin 1 gene is associated with neurotrophic  and neuroprotective effects in  a transgenic mouse model of AD. We have also shown that presenilin 1 gene expression is associated with a reduction in the levels of cytokines and proinflammatory cytokines in AD brains. Our results provide a novel mechanism by which presenilin 1 gene expression might mediate neurotrophic and neuroprotective effects of Abeta peptide.
Glycogen synthase kinase-3beta (GSK-3beta) is a member of the putative primary cell-associated protein kinase that cleaves and aggregates the paired helical filaments (PHF) related to Alzheimer's disease. While GSK-3beta has been shown to be a member of the so-called filamentous protein kinase family, the central role of GSK-3beta in GSK-3beta aggregation has been somewhat unclear. Here, we have examined
====================
Alzheimer's disease is caused by a combination of genetic and environmental factors. The etiology of Alzheimer's disease is complex and involves a number of brain systems and, in particular, its deposition in the brain, the neuronal and synaptic connections. The protein and tissue found in the brains of patients and their families are identical to those of patients with Alzheimer's disease. Age-related changes in the brain, such as loss of nicotinic acetylcholine receptors, are also related to the neurodegeneration in Alzheimer's disease. The major pathological changes are the formation of the amyloid plaques, Alzheimer's disease-like neurofibrillary tangles and beta-amyloid plaques. Alzheimer's disease often causes a neuronal degeneration, such as Alzheimer's disease-like protein deposits, and the loss of the basal forebrain cholinergic neurons is associated with the formation of amyloid deposits. This is the main pathological feature in Alzheimer's disease. Abnormal protein deposits, such as the collagen-associated beta-amyloid plaques, are the major pathological features in Alzheimer's disease. The clinical and pathological features of Alzheimer's disease are similar to those of the other senile dementia  and Alzheimer's disease. The distribution of the amyloid
====================
Alzheimer's disease is caused by the accumulation of amyloid-beta-peptides (Abeta) in the brain of patients with Alzheimer's disease (AD). Despite the recent discovery of Abeta monomers in the brain of patients with AD, the mechanism by which Abeta accumulates and its ability to form plaques and neurofibrillary tangles in AD remains controversial. We investigated the effect of a low-fat diet on plaque formation in AD. Western blot analysis of the plaque formation and Abeta deposition in the brain demonstrated that Abeta was generated in the presence of a low-fat diet. The present results suggest that the low-fat diet might be beneficial for the prevention and treatment of AD.
Schizophrenia (SAD) is the most common cause of dementia in the elderly. In the previous years, a number of anticholinesterase drugs have been developed to treat schizophrenia. In this review, we review the current state of the field and possible directions for future research.
The amyloid (Abeta) peptide is a key component of senile plaques in Alzheimer's disease (AD) and, more recently, in the Huntington's disease (HD). The localization of the Abeta peptide in brains of
====================
Alzheimer's disease is caused by an abnormal deposition of beta-amyloid plaques. A growing body of evidence suggests that beta-amyloid is produced by the extracellular beta-amyloid  peptides, which have been implicated in an important role in the pathogenesis of Alzheimer's disease. However, the precise mechanisms of Abeta deposition are not clear. In the present study, we investigated the effect of pretraining  Tg2576 cells, a model of Alzheimer's disease, on the pathogenesis of Alzheimer's disease. Pretraining by Tg2576 cells transiently induced tau hyperphosphorylation and in vitro expression of the ubiquitin-proteasome system. Immunoblotting of Abeta(1-40) and tau(1-42) peptides was performed to compare the effect of pretraining Tg2576 cells and wild-type cells on Abeta(1-40) and tau(1-42) plaques. Pretraining cells displayed increased levels of tau(1-42) and tau(1-42) peptides. Pretraining cells generated tau(1-42) but not tau(1-42) plaques, indicating that pret
====================
Alzheimer's disease is caused by a progressive loss of cholinergic neurons and the loss of presynaptic terminals in the substantia nigra,  the major source of neuronal activity in the brain. Cholinergic deficits are associated with impaired memory and learning in the hippocampus of Alzheimer's disease.  The most  common course of cholinergic dysfunction in Alzheimer's disease is the formation of wild-type, non-nucleus-cholinergic cells that are expressed exclusively in the substantia nigra and possess presynaptic terminals. The cholinergic system in Alzheimer's disease is not dependent on the presence or absence of presynaptic terminals.  It is not detectable in normal or diseased subjects and it is not detectable in Alzheimer's disease. The lack of a loss of presynaptic terminals suggests that presynaptic terminals, which are thought to be critical for memory, are of higher commonality with other neurons in the substantia nigra. In the absence of presynaptic terminals, there is no discernible loss of presynaptic neuronal activity, which is characteristic of Alzheimer's disease. In contrast, presynaptic terminals are found in the substantia nigra and possess cortex and subiculum terminals, and the subiculum terminal is characterized
====================






Alzheimer's disease should be treated with anti-inflammatory drug, ibuprofen, which improves the effects of ibuprofen on the inflammatory response. The compound ibuprofen is also found to reduce the rate of  neuronal apoptosis in Alzheimer's disease and to increase the survival of microglia cells.
The authors report the development of a novel, novel, active antihealing agent that may be useful as a means of blocking the induction of apoptosis in the brain. The drug combination (ICR) A2805 and A2806 are able to inhibit the induction of neuronal apoptosis in patients with the Alzheimer's disease (AD). This Anti-apoptotic Antibody has been demonstrated to be effective as a treatment for AD and other neurodegenerative disorders.
An investigation of cytochrome P450 (CYP450) related molecules was performed in the present study. The results show that CYP450 is positively related to Alzheimer's disease (AD) and that the C-terminal fragment C695 is related to the disorder. These results suggest that the C-terminal fragment C695 is a critical component of the C-terminal  sequence of the C-terminal  region of the C-terminal portion of
====================
Alzheimer's disease should be treated with caution. The clinical manifestations  of Alzheimer's disease are not always well defined. A diagnosis of probable Alzheimer's disease should be made by a clinician with clinical criteria for Alzheimer's disease. The diagnosis of Alzheimer's disease may be difficult in the early stages, especially in those who do not have a high level of education. There is no cure for Alzheimer's disease.
OBJECTIVE: To determine whether there is a relationship between the number of novel cases of Alzheimer's disease and the age of the patient. METHODS: Two hundred and twelve patients with probable Alzheimer's disease and a total of 101 patients with probable Alzheimer's disease were included in this study. The number of novel cases of Alzheimer's disease and the age of the patient were determined by comparing the number of patients with probable Alzheimer's disease with that of the complete cohort. The number of novel cases of Alzheimer's disease was calculated by dividing the number of patients with probable Alzheimer's disease by the number of patients with probable Alzheimer's disease. RESULTS: The number of novel cases of Alzheimer's disease was significantly higher in patients with probable Alzheimer's disease compared with those with probable Alzheimer's disease (p less than 0.001). The number of novel cases of Alzheimer's disease was
====================
Alzheimer's disease should be treated with caution, particularly in patients with severe dementia of the Alzheimer type.
PURPOSE: To examine the relationship between gene expression in the cortical and entorhinal cortex across the normal and Alzheimer's disease (AD) groups. METHODS: A total of 1010 patients with AD (mean age: 71.0 years; range: 70-87 years) with normal and mild cognitive impairment (mean age: 77.0 years; range: 77-83 years) (n=133) and AD (mean age: 72.0 years; range: 73-79 years) (n=143) were studied. RESULTS: In the normal group, gene expression was decreased in the entorhinal cortex (P=0.004, equal to 0.11). In the AD group, gene expression was increased relative to that in the normal group (P=0.005, equal to 0.14). No significant differences in gene expression were found in the Alzheimer's group compared to the normal group. CONCLUSION: The association between gene expression in the entorhinal cortex and the AD group is not consistent with the association between gene expression in the entorhinal cortex and the normal group.
BACK
====================
Alzheimer's disease should be treated with caution. Further studies are needed to clarify the role of converging pathogenic factors, including fibril formation, in the pathogenesis of Alzheimer's disease.
OBJECTIVE: To determine if institutionalized patients with Alzheimer's disease (AD) have a more significant improvement of cognitive function over time than patients with other dementias. BACKGROUND: Baseline cognitive function measures are based on measures of executive functioning and memory. The aim was to determine whether the results of memory tests can be used to discriminate AD from other dementias. METHODS: Twenty-seven institutionalized patients with AD, who were randomly assigned to two groups, were examined by two cognitively normal volunteers, and the comparison group was identified using neuropsychological tests. The cognitive test scores were compared with those obtained from a group of other dementia patients. RESULTS: Compared with the comparison group, the cognitive test scores were significantly improved in the comparison group when the comparison group was in the treatment group. CONCLUSIONS: This study demonstrates the effect of  institutionalization on memory testing performance.
The aim of this study was to evaluate the efficacy of tacrine in the treatment of patients with dementia of the Alzheimer type (DAT). New data were obtained from a six
====================
Alzheimer's disease should be treated with  a high dose of nonsteroidal anti-inflammatory drugs (NSAIDs). Recently, we demonstrated that the short form of beta-amyloid (Abeta) peptide, produced in the brain-blood buffer fraction, is able to bind the amyloid beta-peptide, Abeta(1-42) peptide, and the amyloid beta-peptide to induce apoptotic growth in wild-type mouse astrocytes. These results strongly support the hypothesis that Abeta(1-42) is a key factor in the pathogenesis of Alzheimer's disease.
Oxidative stress is involved in the pathogenesis of Alzheimer's disease (AD). Recent studies have shown a strong association between oxidative stress and the development of AD. In the present study, we employed the antioxidant vitamin B12, a member of the vitamin B12-rich group of vitamin B12, to investigate the neuroprotective effects of vitamin B12 against oxidative stress. We conclude that this vitamin B12-rich vitamin B12 interacts with the cytochrome P450 system to exert the antioxidant effect on the brain  and neuroblasts. In addition, we found that this vitamin B12-rich antioxidant is able to
====================





Alzheimer's disease should be treated with anti-inflammatory drug, ibuprofen, which improves the effects of ibuprofen on the inflammatory response. The compound ibuprofen is also found to reduce the rate of  neuronal apoptosis in Alzheimer's disease and to increase the survival of microglia cells.
The authors report the development of a novel, novel, active antihealing agent that may be useful as a means of blocking the induction of apoptosis in the brain. The drug combination (ICR) A2805 and A2806 are able to inhibit the induction of neuronal apoptosis in patients with the Alzheimer's disease (AD). This Anti-apoptotic Antibody has been demonstrated to be effective as a treatment for AD and other neurodegenerative disorders.
An investigation of cytochrome P450 (CYP450) related molecules was performed in the present study. The results show that CYP450 is positively related to Alzheimer's disease (AD) and that the C-terminal fragment C695 is related to the disorder. These results suggest that the C-terminal fragment C695 is a critical component of the C-terminal  sequence of the C-terminal  region of the C-terminal portion of
====================
Alzheimer's disease should be treated with caution. The clinical manifestations  of Alzheimer's disease are not always well defined. A diagnosis of probable Alzheimer's disease should be made by a clinician with clinical criteria for Alzheimer's disease. The diagnosis of Alzheimer's disease may be difficult in the early stages, especially in those who do not have a high level of education. There is no cure for Alzheimer's disease.
OBJECTIVE: To determine whether there is a relationship between the number of novel cases of Alzheimer's disease and the age of the patient. METHODS: Two hundred and twelve patients with probable Alzheimer's disease and a total of 101 patients with probable Alzheimer's disease were included in this study. The number of novel cases of Alzheimer's disease and the age of the patient were determined by comparing the number of patients with probable Alzheimer's disease with that of the complete cohort. The number of novel cases of Alzheimer's disease was calculated by dividing the number of patients with probable Alzheimer's disease by the number of patients with probable Alzheimer's disease. RESULTS: The number of novel cases of Alzheimer's disease was significantly higher in patients with probable Alzheimer's disease compared with those with probable Alzheimer's disease (p less than 0.001). The number of novel cases of Alzheimer's disease was
====================
Alzheimer's disease should be treated with caution, particularly in patients with severe dementia of the Alzheimer type.
PURPOSE: To examine the relationship between gene expression in the cortical and entorhinal cortex across the normal and Alzheimer's disease (AD) groups. METHODS: A total of 1010 patients with AD (mean age: 71.0 years; range: 70-87 years) with normal and mild cognitive impairment (mean age: 77.0 years; range: 77-83 years) (n=133) and AD (mean age: 72.0 years; range: 73-79 years) (n=143) were studied. RESULTS: In the normal group, gene expression was decreased in the entorhinal cortex (P=0.004, equal to 0.11). In the AD group, gene expression was increased relative to that in the normal group (P=0.005, equal to 0.14). No significant differences in gene expression were found in the Alzheimer's group compared to the normal group. CONCLUSION: The association between gene expression in the entorhinal cortex and the AD group is not consistent with the association between gene expression in the entorhinal cortex and the normal group.
BACK
====================
Alzheimer's disease should be treated with caution. Further studies are needed to clarify the role of converging pathogenic factors, including fibril formation, in the pathogenesis of Alzheimer's disease.
OBJECTIVE: To determine if institutionalized patients with Alzheimer's disease (AD) have a more significant improvement of cognitive function over time than patients with other dementias. BACKGROUND: Baseline cognitive function measures are based on measures of executive functioning and memory. The aim was to determine whether the results of memory tests can be used to discriminate AD from other dementias. METHODS: Twenty-seven institutionalized patients with AD, who were randomly assigned to two groups, were examined by two cognitively normal volunteers, and the comparison group was identified using neuropsychological tests. The cognitive test scores were compared with those obtained from a group of other dementia patients. RESULTS: Compared with the comparison group, the cognitive test scores were significantly improved in the comparison group when the comparison group was in the treatment group. CONCLUSIONS: This study demonstrates the effect of  institutionalization on memory testing performance.
The aim of this study was to evaluate the efficacy of tacrine in the treatment of patients with dementia of the Alzheimer type (DAT). New data were obtained from a six
====================
Alzheimer's disease should be treated with  a high dose of nonsteroidal anti-inflammatory drugs (NSAIDs). Recently, we demonstrated that the short form of beta-amyloid (Abeta) peptide, produced in the brain-blood buffer fraction, is able to bind the amyloid beta-peptide, Abeta(1-42) peptide, and the amyloid beta-peptide to induce apoptotic growth in wild-type mouse astrocytes. These results strongly support the hypothesis that Abeta(1-42) is a key factor in the pathogenesis of Alzheimer's disease.
Oxidative stress is involved in the pathogenesis of Alzheimer's disease (AD). Recent studies have shown a strong association between oxidative stress and the development of AD. In the present study, we employed the antioxidant vitamin B12, a member of the vitamin B12-rich group of vitamin B12, to investigate the neuroprotective effects of vitamin B12 against oxidative stress. We conclude that this vitamin B12-rich vitamin B12 interacts with the cytochrome P450 system to exert the antioxidant effect on the brain  and neuroblasts. In addition, we found that this vitamin B12-rich antioxidant is able to
====================



Using dataset with papers published till 2020


Alzheimer's disease is caused by an imbalance between  synaptic and cholinergic precursors. We have previously shown that the density of the cholinergic precursors is reduced in the hippocampus of mice suffering from AD (p = 0.04). Here, we investigated the effects of apolipoprotein E (apoE) on the hippocampal cholinergic precursors by binding them with the PG-2A2-R yamikit, an apolipoprotein E (apoE)-deficient mouse model. The interaction of apoE with the PG-2A2-R yamikit reduced the volume of the hippocampal cholinergic precursors (p = 0.04) and the  dentate gyrus (p = 0.04) in the mouse model, and induced a decrease in the density of the hippocampal cholinergic precursors (p < 0.05). These results revealed that apoE-mediated cholinergic dysfunction in the hippocampus is caused by an imbalance between the cholinergic precursors and the PG-2A2-R yamikit. In addition, apoE-mediated cholinergic dysfunction in the hippocampal cholinergic precurs
====================
Alzheimer's disease is caused by the accumulation of toxic  proteins, which are known to play a role in the pathogenesis of the disease. In this paper, we summarize the current knowledge regarding the role of the protein-protein interaction in the pathogenesis of Alzheimer's disease. We also discuss the biochemical and clinical implications of the interaction, considering that involved in the proteolytic processing of the protein-protein interaction is a redox-insoluble proteolytic pathway, which has been implicated in the pathology of Alzheimer's disease.
The beta-amyloid peptide, expressed in a transmembrane region of the apolipoprotein E (apoE) epsilon4 allele, has been implicated in the pathogenesis of Alzheimer's disease (AD). In this study, we used a novel, high-throughput, double-molecule [3H]polymerase chain reaction (PCR) method to identify the beta-amyloid peptide and the apoE epsilon4 allele in two transgenic mouse models of AD. The enzyme, which is activated in AD mouse, was expressed in the apoE epsilon4/apoE epsilon4/apoE epsilon3/apoE
====================
Alzheimer's disease is caused by defective protein processing of amyloid precursor protein (APP) and deposition of the amyloid precursor protein in the brains of transgenic mice. Interestingly, APP is a key player in the pathogenesis of Alzheimer's disease. APP is a major player in the pathogenesis of amyloidosis in neurons and it is involved in the regulation of neuronal cell cycle and synaptic plasticity. It is also the major player in the neuroinflammatory process and plays a critical role in  our understanding  of the pathogenesis of neurofibrillary changes and their role in the neurodegenerative process. APP is a potential candidate for treatment of Alzheimer's disease because it has demonstrated  clinical benefits in animal models. APP is a polypeptide that seems to be intimately linked with the development of neurofibrillary diseases such as Alzheimer's, Parkinson's and Huntington's diseases. In this review, we have briefly reviewed the role of APP in the neurodegenerative process and its potential therapeutic potential.
The structure and function of calcineurin are key  in the well-known role of calcineurin in the management of Alzheimer's disease. We have previously shown that the presence of calcineurin in the brain of normal elderly
====================
Alzheimer's disease is caused by a neuritic protein called amyloid-beta. Amyloid-beta is a neurotoxic polypeptide that is present in amyloid-beta plaques. The amyloid-beta protein is produced by the intracellular accumulation of amyloid-beta in neurons.  Amyloid-beta also causes neurodegeneration, neurotoxicity, and neuroinflammation. Amyloid-beta has been implicated in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. Amyloid-beta is found in brain parenchyma, cerebral ischemia, and ischemia of the brain. Amyloid-beta has been found in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Inhibitors of amyloid-beta have  been proposed as potential therapeutic agents for neurodegenerative diseases, especially Alzheimer's disease. Here we report the identification of two novel inhibitors of amyloid-beta, Thioflavin-1 and Thioflavin-3. We furthermore report the identification of these two inhibitors of amyloid-beta as potential agents for the
====================
Alzheimer's disease is caused by a mutation in the gene for beta-amyloid (A beta) that predisposes to the development of senile plaques. The mutations in the allele for A beta (A beta) cause post-translational modifications that cause the accumulation of Abeta plaques. The mutation causes Abeta to form aggregated plaques, the most prominent of which is the large-branching protein, that is packed in the outermost compartment of Abeta. Interestingly, the plaques are composed of a combination of the two alleles. Through the regulation of the beta-amyloid protein  and the regulation of the beta-secretase enzyme, Abeta plaques are able to form in vitro and in vivo. The aggregation activity of Abeta plaques occurs through the interaction of the two proteins and the binding sites of the beta-secretase enzyme. The hyperphosphorylation of the beta-secretase is a common feature of Alzheimer's disease and correlates with the aggregation defects. Our findings suggest that Abeta aggregation may be a crucial process  in the process of Abeta aggregation.
The beta-amyloid precursor protein (beta-APP) is a member of the amyloid precursor protein family with the
====================

Alzheimer's disease is caused by an imbalance between the brain's ability to generate and maintain  the essential neuronal connections that make up the neuroprotective system. In this study, we have synthesized a novel, anti-amyloidate-derived polypeptide, a 5-methoxy-2,3,4-diphenyl-glutaryl-glutaryl-glutaryl-stearic acid (HGA-glutaryl) (2(2-hydroxynyl)ethoxy), an antimerized form of the amyloidogenic peptide in a class with a carbon monomer formed by a regular denaturing process of the peptide, and an amyloidogenic-like form of HGA-glutaryl-glutaryl-glutaryl-stearic acid (HGA-glutaryl) (2(2-hydroxynyl)ethoxy) (1, 2H, 1,2H, 1,2H, 1,2H, 1,2H, 1,2H, 1,2H, 1,2H, 1,2H, 1,2H, 1,2H, 1,2H, 1
====================
Alzheimer's disease is caused by degeneration of neurons in the hippocampus, but the initial damage is sustained. Decreased levels of p38, tyrosine hydroxase and neurotrophin are likely the consequences of the degeneration. The aim of this study was  to investigate the effects of increased p38, tyrosine hydroxase and neurotrophin on c-Jun N-terminal kinase (JNK) activity and the protein kinase Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/Akt/A
====================
Alzheimer's disease is caused by the accumulation of amyloid beta (Abeta) peptide and by the aggregation of senile plaques. In this study, we examined whether the expression of N-acetyl aspartate (NAACT), a key regulator of neurogenesis, was decreased in Drosophila melanogaster (D. melanogaster) after the transgenic overexpression of Abeta1-42. We found that inhibition of N-acetyl N-acetyltransferase 5A (N-ACT-5A) mRNA significantly reduced the expression of N-acetyl aspartate in D. melanogaster compared with wild-type controls. N-acetyl aspartate-dependent induction of N-acetylaspartate (N-ACT-5A) stimulated the expression of N-acetylaspartate (N-ACT-5A) in D. melanogaster, with no effect. This may be a mechanism for N-acetylaspartate-dependent induction of N-acetylaspartate (N-ACT-5A) by N-acetyl aspartate.
BACKGROUND: The functional significance of white matter (WM) atrophy in Alzheimer's disease
====================
Alzheimer's disease is caused by a malfunctioning of the amyloid precursor protein, A beta, which leads to the development of beta-amyloid deposits similar to those seen in Alzheimer's disease. There is a growing body of evidence that the development of beta-amyloid has a role  in the pathogenesis of this disorder. A beta-amyloid, which has been reported to be neurotoxic, has been reported to be neurotoxic in neuronal and glial cells. Humans have been shown to be neurotoxic in brain-derived neurotrophic factors (BDNF) and in neurons in the dentate gyrus of the hippocampus, an area of astrocytes in which BDNF and other neurotrophic factors are found. In humans, resting tau protein levels have been demonstrated  to be a biomarker for tau pathology in Alzheimer's disease. Whether this is a cause of tau pathology is not clear. The present study aims at demonstrating the therapeutic efficacy of the anionic drug, the compound piperidine, in controlling tau pathology in a mouse model of tauopathy. The results indicated that piperidine reduced the tau pathology in a murine model of tauopathy, as compared to a control group. The animal model
====================
Alzheimer's disease is caused by an imbalance between the beta-amyloid (beta-amyloid) precursor protein (Abeta) processing and its precursor  beta-amyloid (beta-amyloid)  precursor. Abeta is the major component of the amyloid precursor protein. This imbalance may result in the production of Abeta in the brain. As the beta-amyloid precursor protein is encoded and expressed in  the brain, the Abeta production may result in increased Abeta production and a reduction in Abeta clearance. In this study, we investigated the effect of Abeta overexpression on Abeta production in human primary hippocampal neurons. In a double transgenic model of Alzheimer's disease, we measured Abeta levels in hippocampal neurons in the absence of Abeta. We found that Abeta-mediated cleavage of the Abeta precursor protein produced Abeta that was diminished in the hippocampus compared to controls. In contrast, the Abeta-mediated release of Abeta and the decrease in Abeta clearance of Abeta in the hippocampus were not affected by Abeta overexpression. Neither Abeta nor Abeta40 was reduced in the hippocampus. In addition, we found that Abeta40 overexpression significantly reduced Ab
====================



Alzheimer's disease should be treated with the same therapeutic strategies as for other dementias.
The amyloid-beta (Abeta) peptide, which is used to synthesize the amyloid precursor protein, is one of the major drivers of neurodegenerative diseases, including Alzheimer's disease. Here, we report that the amyloid-beta peptide exerts its beneficial effects by activating the transcription of the gene, and by enhancing its expression with a transcriptional response that becomes highly expressed. This transcriptional response affects the expression of several genes, including the protein phosphatase A, the protein phosphatase C, the protein phosphatase CII, the protein phosphatase B, the protein phosphatase CII, the protein phosphatase A and the protein phosphatase C. In  addition, the transcription of the gene in neuronal and glial cells, as well as the expression of the gene in the neuropathological stably transfected rat model of Alzheimer's disease, is also inhibited by the peptide. Inhibition of the transcription of all three proteins, together with the signalling activity of the gene, also suppresses the expression of the genes. In addition, the gene expression of all three proteins in the neuronal and
====================
Alzheimer's disease should be treated with anti-aggregation agent as an antiamyloid therapy.
OBJECTIVE: The aim of this study was to evaluate the effect of  an oral formulation of the apolipoprotein E (ApoE) epsilon 4 allele on Alzheimer's disease (AD) and its role in the pathogenesis of AD. METHODS: In this study, we used the apolipoprotein E (ApoE) epsilon 4 allele to evaluate the effects of apolipoprotein E (ApoE epsilon 4) on AD-like pathology in two independent samples. The epsilon 4 allele was found to be associated with a significant increase in AD-like pathology, but not in the other two alleles. The beta-actin and tau phosphorylated Tau (Ptau) were significantly increased in AD-like pathology, but not in the other two alleles. The ApoE genotype was also found to be associated with a greater increase in AD-like pathology. The change in the alpha-synuclein and gamma-synuclein levels in AD-like pathology was similar in both the ApoE and apo E epsilon 4 isoforms, whereas
====================
Alzheimer's disease should be treated with the most appropriate anti-cancer drug available (as a selective agent),  and first to be used as a  treatment for Alzheimer's disease.
Alzheimer's disease is a neurodegenerative disorder characterized by progressive memory loss which is characterized by an accumulation of amyloid-beta protein (Abeta) peptides and neurofibrillary fibrils. The Abeta plaques consist of plaques composed of many toxic species, such as amyloid beta-1-42, the neurotoxic species of which are the major components of the amyloid plaques, and the neurotoxic species of which are the neurotoxic Abeta species of which are the neurotoxic species of which are the Abeta species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurotoxic species of which are the neurot
====================
Alzheimer's disease should be treated with a combination of anti-depressants and antidiabetic drugs. Pharmacokinetic studies indicate that the extract of the plant nusculotus (N. obra) is the only active component of the plant that is able to inhibit the enzyme tyrosine hydroxylase (TUR) 2.2.1. In vitro, the extract of nusculotus is able to inhibit the activity of the enzyme, but it is not able to alter the activity of tyrosine hydroxylase (TUR) 2.2.1. These results suggest that the extract of nusculotus is able to inhibit the activity of the enzyme, but it is not capable of modifying the activity of the enzyme. The mechanisms of this action are discussed.
BACKGROUND: Alzheimer's disease (AD) is characterized by the aggregation of amyloid-beta (Abeta) peptide into various insoluble fragments. The search for new agents for AD has focused on targeting Abeta, a member of the amyloid precursor protein (APP) that is found in the brain. The aim of this study was to determine the ability of a three-dimensional antibody to cleave APP, with a solub
====================
Alzheimer's disease should be treated with the primary prevention strategy: drugs with additional side effects.
The assembly and purification of amyloid precursor protein (APP) by beta-secretase (BACE1) has been used in the etiology of Alzheimer's disease. However, the  potential role of this enzyme in the initiation and progression of the neurodegenerative disease is still largely unexplored. In this study, we determined the  presence of a new enzyme, beta-secretase, in the APP precursor, beta-amylase (ASP), in human amyloid precursor protein (APPs) from the brains of Alzheimer's disease (AD) and control brains, using immunocytochemistry. We found that as the amino acid of ASP, tau, inhibited the formation of ASP, but not tau, in AD and control brains. Moreover, ASP-deficient brains had a decreased density of tau in the frontal cortex of AD and controls, but not in AD brains. We also found that the  expression of BACE1 in AD and controls was increased inducible in the frontal cortex of AD and control brains. In this study, we found that beta-secretase plays a role in the initiation and progression
====================


Alzheimer's disease should be treated with the use of paracetamol, an active agent in the treatment of Alzheimer's disease, for the prevention of dementia.
Mammalian neurons are in close association with several major neuronal systems that are involved in many neurological diseases such as Alzheimer's disease. Mammalian neurons constitute the nucleus of the basal forebrain (BM) and its basal outer layer (AB), which is the brain's primary organ. The BBB is the crucial organ in the regulation of normal cells. In this paper, we propose a novel model for the relationship between the BBB and the mammalian brain. In a previous study, we used the same method to model the BBB and the AB in a mouse model of Alzheimer's disease. We have developed a model of the BBB, which is based on the spontaneous transport of senile plaques  and autophagic lesions and the initiation of the injury process, and we have also developed a model of the BBB in a mouse model of the disease. We have found that the BBB in the mouse is  the most active organ in the BBB, and the BBB is also the most active organ in the adult body. We have also studied the role of the BBB in the pathophysiology
====================
Alzheimer's disease should be treated with the same care as a normal adult (i.e., use of food and water), as the care of a dementia patient is often less than optimal.
The amyloid-beta (Abeta) peptide is a major pathological charge in Alzheimer's disease. The deleterious effect of Abeta on synaptic transmission has been reported to be due to its accumulation of soluble Abeta species. This study is aimed to assess the effect of Abeta on the acetylcholine (ACh) receptor-mediated signal transduction in the hippocampal CA1 region of the rat. ACh-mediated signaling was also investigated in the hippocampal CA1 region of the rat using an anti-AChCl2 antibody. ACh receptors and their receptors were also phosphorylated by the fluorescence assay in the hippocampus. The levels of ACh receptor and receptor-encoded proteolytic enzymes were significantly increased in the hippocampus compared with the control and the AD rats. The levels of ACh receptor and receptor-encoded proteolytic enzymes were also decreased in the hippocampus of the AD rats. The expression of the human ACh receptor mRNA was significantly decreased in AD rats. The expression of ACh receptor mRNA was significantly increased in the
====================
Alzheimer's disease should be treated with an active, but usually non-competitive, agent of Abeta.
The neuropil from Caenorhabditis elegans is a rare but important population of cells that is essential for learning and memory. The cerebral cortex is very often composed of a large number of neurons; however, the complexity of the cerebral cortex is  yet to be elucidated and the cellular mechanisms of the cerebral cortex are still a matter of great investigation. The cerebral cortex is a place that is considered to be composed of many organs  that are mostly active, including the cerebral cortex and the glia. One of the main functions of the cerebral cortex is the identification of neurons and glia. In addition, the brain has a number of neurites, which are selectively involved in the nervous system, which are involved in many neurological processes such as the nervous system and the  central nervous system. In general, the neurites are located in the brain, and are the major organ that is involved in learning and memory. The neurites are the major organ involved in the nervous system. The neurites are also the main organ involved in the neuroinflammation, which in turn is the main organ involved in the formation of neurofibrillary lesions. The neur
====================
Alzheimer's disease should be treated with a combination of neuroprotective and anti-apoptotic drugs.
Alzheimer's disease is a neurodegenerative disease that is characterized by the accumulation of senile plaques of the Alzheimer's disease, with amyloid-beta protein as the major component. The amyloid-beta protein is a peptide derived from the amyloid precursor protein, amyloid-beta40, which has been shown to be involved in the generation of amyloid-beta precursor protein and also in the pathogenesis of Alzheimer disease. Oxidative stress plays a key role in the pathogenesis of  Alzheimer's disease and can be activated by multiple mechanisms such as oxidative stress, inflammatory cascade, and beta-amyloidogenic signaling. Oxidative stress plays a key role in the development of neurodegenerative diseases such as Alzheimer's disease. In this study, we report that in mice lacking the amyloid-beta protein, the amyloid-beta peptide is able to promote the expression of a newly identified anti-amyloidogenic signal (genotype 4), which is associated with the generation of amyloid-beta40. In C57BL/6J mice, amyloid-
====================
Alzheimer's disease should be treated with a full complement of anti-amyloid agents, including anticholinesterase, memantine, and memantine moieties, and a more selective and specific anti-amyloid agent, memantine moiety.
The molecular mechanism of the neurotrophic factor (Nrf) is complex. Inhibitors of Nrf function are involved in an important  role in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A few Nrf inhibitors have been identified. This may involve dual-targeting of Nrf and Nrf-dependent pathways. Herein we have investigated the effects of an atomic force microscope assay on the Nrf-dependent pathways in these proteins. In the case of the Nrf-related Nrf1/Nrf2 complex, a crucial step in Nrf-dependent proteolysis is the 2-phosphorylation of Nrf. The critical step in this process is the cleavage of the Nrf-specific binding domain (NrfIC) into a Nrf-dependent domain. We used a modified Nrf-dependent enzyme (Nrf2D) to show that Nrf2D is a Nrf-dependent protein. Nrf2D is a
====================


Alzheimer's disease is characterized by a decrease in brain-derived neurotrophic factor (BDNF) and decreased brain-derived neurotrophic factor (BDNF) concentrations. In  this study, we investigated the effect of two doses of alpha-synuclein (M1 and M2), a flavonoid with anti-BDNF, on the androgen and estrogen receptor subunits (ERs) in the hippocampus and postcentral gyrus (cGluR), a nucleolus-containing subcellular structure located in the hippocampus in Alzheimer's disease. M1 and M2 were administrated in the hippocampus for 4 h and then  the assay was repeated in the cGluR subcellular region (CGR). The M1 and M2 dose of M1 and M2 completely suppressed the decrease of BDNF levels in the cGluR subcellular regions, whereas the M1 dose suppressed the increase of BDNF levels in the cGluR subcellular region. Furthermore, the M1 dose of M2 significantly decreased the BDNF levels in the cGluR subcellular region and CGR. Furthermore, M1 also significantly increased the BDNF levels in the CGR subcellular region (P < 0
====================
Alzheimer's disease is characterized by progressive impairment of memory. The aim of the present study is to develop a novel, single-photon emission computed tomography (3-CT) probe for the endoplasmic reticulum (ER) and to determine whether it contributes to the  diagnosis of one.
The aim of the present study was to investigate whether (i) the presence of beta-amyloid (Abeta) in the brain of patients with Alzheimer's disease (AD) could be a risk factor for the development of AD. In this study, the density of Abeta in the brain of patients with AD was measured using a polysomnography technique and the levels of Abeta were measured using two-dimensional (2D) nanomolar electron tomography. The concentrations of Abeta were measured using a molecular radioimmunoassay method. The levels of Abeta were determined by the ELISA method and in the presence of Abeta in blood. The levels of Abeta were significantly decreased in the presence of Abeta, but not in the absence of Abeta. (ii) Abeta was found to be an important risk factor for the development of AD in the cerebrospinal fluid.
The most important neuroim
====================
Alzheimer's disease is characterized by the presence of neurofibrillary tangles that are characterized by only three distinct initial folds: a dense, axonal, and non-axonal subcellular core, and a putative neuritic core, which is subsequently composed of a variety of neurofibrillary tangles. The specific neurofibrillary tangles are characterized by a loss of neurons and neurofibrillary tangles that are abnormally elongated, and a loss of neurons and the neurofibrillary tangles that are elongated remain. The neurofibrillary tangles that are abnormally elongated are characterized by being surrounded by hyperphosphorylated tau, which is a hallmark of Alzheimer's disease, whereas the neurofibrillary tangles that are abnormally elongated are characterized by being surrounded by hyperphosphorylated tau, which is a characteristic of Parkinson's disease.
BACKGROUND: Global cerebral glucose isometabolism is a key mediator of expression of genes involved in several metabolic stress pathways and is an important risk factor for Alzheimer's disease. The present study used a novel, non-amyloidogenic, non-amyloidogenic (non-amyloid-receptor) gene that has been
====================
Alzheimer's disease is characterized by the development of presenilin-1 and presenilin-2/3, a two-truncated protein which is associated with the development of presenilin-1 and presenilin-2/3. The two proteins are expressed in different cell types and have diverse morphologies, suggesting the evolution of a unique RNA-protein family. The RNA-protein family includes the presenilin-1 and presenilin-2/3 isoforms and the two proteins are closely related. The two proteins are associated with neurons and glial cells, but not with other neurons. The two proteins have been proposed to be involved in the pathogenesis of Alzheimer's disease, and their development suggests that presenilin-1 and presenilin-2/3 are involved in the pathogenesis of Alzheimer's disease.
Alzheimer's disease is characterized by the development of senile plaques of amyloid-like protein in brain and surrounding tissue. The levels of amyloid-like protein are increased in  senile plaques of Alzheimer's disease. In contrast, the levels of amyloid-like protein are reduced in the brains of patients with Alzheimer's disease. We
====================
Alzheimer's disease is characterized by a progressive neurodegeneration. The main source of cellular and molecular damage is the production of amyloid-beta (Abeta) peptides. Abeta peptides are believed to be responsible for a variety of diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. We hypothesized that the production of Abeta and its subsequent degradation would be mediated by a "survival-differentiation" mechanism. In this study, we used an  experimental model of Abeta production to model the nature of  its degradation through a "survival-differentiation" mechanism. We demonstrate that the survival-differentiation mechanism of Abeta is mediated by an independent interaction of the protein proteolysis factor PPARgamma with the proteolytic  domain of PPARgamma. The proteolytic domain of PPARgamma is also responsible for the production of Abeta, thus suggesting a survival-differentiation mechanism. In the present study, we observed that Abeta-induced mitochondrial degradation is dependent on the  proteolytic domain of PPARgamma. Furthermore, we found that the levels of PPARgamma are reduced in Abeta-induced mitochondria in  a manner similar to
====================


Alzheimer's disease is characterized by the deposition of amyloid-polypeptide epitopes and by the formation of a mixture of amyloid-beta plaques and neurofibrillary tangles, both of which are highly toxic. There are many sporadic AD cases, and no disease-modifying therapies are available. Here we present a novel, yet remarkably accurate, method of characterizing amyloid-polypeptide epitopes and its toxicity in AD brain. We found that the amyloid-polypeptide-peptide mixture of amyloid-beta and those of amyloid-beta polypeptides is able to up-regulate the expression of the neurotrophic factor alpha superoxide dismutase, which is a key factor in pathological neuronal cell death in AD brain. Furthermore, we compared, using an antibody to BACE1, the synthesis of amyloid-beta and the amyloid-beta-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-peptide-
====================
Alzheimer's disease is characterized by a progressive loss of cognitive functions, with a neuritic disease. The neuropathology is characterized by the conformation of senile plaques in the hippocampus, with a progressive loss of neurons. The neuroinflammation plays a central role in the pathogenesis of Alzheimer's disease. Some of the first  evidences for neuronal injury in Alzheimer's disease were demonstrated by immunohistochemistry and with flow cytometry, which showed the involvement of astrocytes in the neuroinflammatory response. In this study, we show that the accumulation of microglia is induced by the activation of microglial cells, which were specifically activated by the activation of astrocytes. The neuroinflammatory response of microglia was observed in the first neuroinflammatory state, in the second neuroinflammatory state and in the third neuroinflammatory state. The microglial activation resulted in the activation of astrocytes, which were recognized by the expression of the specific receptor on astrocytes, gamma-secretase, which was activated by the activation of astrocytes. The activation of astrocytes was also accompanied by apoptotic cell death in the astrocyte cytoskeleton. In addition, an increase in the expression of microgl
====================
Alzheimer's disease is characterized by the presence of amyloid-beta (Abeta), a class of neurodegenerative diseases, including Alzheimer's disease (AD). A major mechanism for AD is the accumulation of Abeta in the brain and the clearance of Abeta from the brain. In this study, we observed that the administration of Abeta 1-40 [(1,2'-dibutyl]-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,2'-dibutyl-N-methyl-D-aspartate) (1,
====================
Alzheimer's disease is characterized by the presence of a large number of proteins in the brain and the neurofibrillary tangles are a common feature of the disease. The amyloid precursor protein (APP) is a naturally occurring protein in the brain and is the major component of the neurofibrillary tangles. APP is believed to play a key role in the development and differentiation of the nervous system. It has been shown to also be a key player in the pathogenesis of many diseases, including stroke, Alzheimer's disease, and cancer. In this study, we examined the neurofibrillary structures in the brains of patients with Alzheimer's disease (AD) and control (HC) mice and found that APP is found in the neurofibrillary structures. We also showed that APP is present in the central nervous system (CNS) and brain of AD mice and that APP is also present in the CNS of HC mice, suggesting that APP plays a key role  in the CNS and other aspects of the nervous system.
In this study, we tested the hypothesis that the processing of peptide N-terminal fragments (TdN) in neuronal cell models of Alzheimer's disease (AD) was different from that of healthy controls. In the hippocampus of mice
====================
Alzheimer's disease is characterized by stalling of the protein, which is necessary to regulate the protein's cycle and thus is one of the earliest events affected by Alzheimer's disease. In this process, the protein undergoes an elevation of phosphorylation, which is necessary for its  ability to protect the cell from the damage caused by intracellular proteolysis, a process that may have a role in Alzheimer's disease pathology. In order to understand how protein phosphorylation is involved in Alzheimer's disease, we have studied the expression of a key protein-protein interaction protein with the glycoprotein 1 (GPI1) in mouse brain. By using the mouse GPI1, we show that GPI1 expression is significantly increased in the AD mouse brain, at a ratio of 1:1, whereas GPI1 isoforms are significantly decreased in the AD mouse brain. Furthermore, we show that GPI1 expression is significantly reduced in the AD mouse brain, and the expression of GPI1 isoforms is significantly increased in the AD mouse brain. This may be the basis for the observed increase of GPI1 expression in AD mice.
BACKGROUND: Alzheimer's disease, including amnestic mild cognitive impairment (aMCI), is a neurodegener
====================